^
    3d
    T-cell chromatin states reflect individual differences in ex vivo cytokine release and cytotoxicity induced by T-cell engager ERY22 in cynomolgus monkeys. (PubMed, Toxicol Sci)
    We used ERY22, a T-cell engager developed as a monkey surrogate of the human therapeutic candidate ERY974, an anti-GPC3/CD3 T-cell engager...Interindividual variability in cytokine production and cytotoxicity correlated with chromatin accessibility at loci associated with these processes. These findings advance understanding of personalized risk prediction and management of CRS in clinical settings.
    Preclinical • Journal
    |
    GPC3 (Glypican 3)
    |
    ERY974
    23d
    ARYA3: GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Eureka Therapeutics Inc. | N=20 --> 60
    Enrollment change
    |
    GPC3 (Glypican 3)
    |
    ECT204
    2ms
    BGB-B2033-101: A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=392, Recruiting, BeOne Medicines | N=140 --> 392 | Trial completion date: Dec 2026 --> May 2028 | Trial primary completion date: Oct 2026 --> May 2028
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    AFP (Alpha-fetoprotein) • GPC3 (Glypican 3)
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr)
    3ms
    BGB-B2033-101: A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors (2025-524136-19-00)
    P1, N=56, Not yet recruiting, BeOne Medicines AG
    New P1 trial
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr)
    3ms
    Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC (clinicaltrials.gov)
    P1/2, N=590, Recruiting, RayzeBio, Inc. | Phase classification: P1 --> P1/2 | N=70 --> 590 | Trial completion date: Jan 2031 --> Jun 2031 | Trial primary completion date: Mar 2029 --> Jun 2030
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    3ms
    BANTAM-01: A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer (clinicaltrials.gov)
    P1, N=148, Recruiting, Bayer | Trial completion date: Dec 2033 --> Aug 2031 | Trial primary completion date: Jul 2030 --> Jul 2029
    Trial completion date • Trial primary completion date • First-in-human
    |
    GPC3 (Glypican 3)
    4ms
    A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment (clinicaltrials.gov)
    P1, N=50, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    GPC3 (Glypican 3)
    |
    codrituzumab (RG7686)
    6ms
    Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=33, Terminated, Sanofi | Active, not recruiting --> Terminated; Early discontinuation based on strategic sponsor decision not driven by any safety concerns
    Trial termination • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • GPC3 (Glypican 3)
    |
    Tecentriq (atezolizumab) • SAR444200
    6ms
    NWRD06 DNA Plasmid for HCC After Curative Resection. (clinicaltrials.gov)
    P2, N=30, Recruiting, Newish Technology (Beijing) Co., Ltd.
    New P2 trial
    |
    GPC3 (Glypican 3)
    6ms
    BANTAM-01: A Multicenter, Open-Label, First-in-Human Phase 1 Dose Escalation and Expansion Study of 225Ac-GPC3 (BAY 3547926) in Patients with Advanced Hepatocellular Carcinoma. (PubMed, J Nucl Med)
    Study recruitment commenced in March 2025, and approximately 148 participants will be enrolled. The study will provide important preliminary insights on the efficacy and safety of 225Ac-GPC3 ACC therapy.
    P1 data • Journal • First-in-human
    |
    GPC3 (Glypican 3)
    7ms
    MTX-GPC3-303: A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC (clinicaltrials.gov)
    P1, N=70, Recruiting, Myeloid Therapeutics | N=48 --> 70 | Trial completion date: May 2026 --> May 2028 | Trial primary completion date: Jul 2025 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    7ms
    Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma. (PubMed, Nat Commun)
    No severe adverse effects or gross pathology were observed. Our results thus support the advancement of MTS105 into clinical trials, with a first-in-human study currently underway.
    Journal
    |
    CD8 (cluster of differentiation 8) • GPC3 (Glypican 3)